PL3536380T3 - Szybko działające kompozycje insuliny - Google Patents

Szybko działające kompozycje insuliny

Info

Publication number
PL3536380T3
PL3536380T3 PL19161129T PL19161129T PL3536380T3 PL 3536380 T3 PL3536380 T3 PL 3536380T3 PL 19161129 T PL19161129 T PL 19161129T PL 19161129 T PL19161129 T PL 19161129T PL 3536380 T3 PL3536380 T3 PL 3536380T3
Authority
PL
Poland
Prior art keywords
acting insulin
fast acting
insulin compositions
compositions
fast
Prior art date
Application number
PL19161129T
Other languages
English (en)
Inventor
Michael Edward CHRISTE
Thomas Andrew HARDY
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53189204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3536380(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL3536380T3 publication Critical patent/PL3536380T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL19161129T 2014-05-08 2015-05-04 Szybko działające kompozycje insuliny PL3536380T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461990402P 2014-05-08 2014-05-08
EP19161129.2A EP3536380B8 (en) 2014-05-08 2015-05-04 Rapid-acting insulin compositions
PCT/US2015/029010 WO2015171484A1 (en) 2014-05-08 2015-05-04 Rapid-acting insulin compositions
EP15723388.3A EP3140008B1 (en) 2014-05-08 2015-05-04 Rapid-acting insulin compositions

Publications (1)

Publication Number Publication Date
PL3536380T3 true PL3536380T3 (pl) 2021-12-27

Family

ID=53189204

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19161129T PL3536380T3 (pl) 2014-05-08 2015-05-04 Szybko działające kompozycje insuliny
PL15723388T PL3140008T3 (pl) 2014-05-08 2015-05-04 Szybko działające kompozycje insuliny

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL15723388T PL3140008T3 (pl) 2014-05-08 2015-05-04 Szybko działające kompozycje insuliny

Country Status (36)

Country Link
US (2) US9439952B2 (pl)
EP (3) EP3943155A1 (pl)
JP (1) JP6050902B2 (pl)
KR (1) KR101858890B1 (pl)
CN (1) CN106456717B (pl)
AP (1) AP2016009525A0 (pl)
AR (1) AR100155A1 (pl)
AU (1) AU2015256355B2 (pl)
BR (1) BR112016024357B1 (pl)
CA (1) CA2945188C (pl)
CL (1) CL2016002772A1 (pl)
CY (2) CY1121669T1 (pl)
DK (2) DK3140008T3 (pl)
EA (1) EA031134B1 (pl)
ES (2) ES2733639T3 (pl)
HR (2) HRP20190777T1 (pl)
HU (2) HUE044370T2 (pl)
IL (1) IL248350B (pl)
JO (1) JO3624B1 (pl)
LT (2) LT3140008T (pl)
MA (1) MA39441A1 (pl)
ME (1) ME03384B (pl)
MX (1) MX367521B (pl)
NZ (1) NZ724919A (pl)
PE (1) PE20161408A1 (pl)
PH (1) PH12016502195B1 (pl)
PL (2) PL3536380T3 (pl)
PT (2) PT3140008T (pl)
RS (2) RS58726B1 (pl)
SG (1) SG11201608424WA (pl)
SI (2) SI3140008T1 (pl)
TN (1) TN2016000443A1 (pl)
TR (1) TR201906843T4 (pl)
TW (1) TWI685348B (pl)
UA (1) UA124919C2 (pl)
WO (1) WO2015171484A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
KR20150082640A (ko) 2012-11-13 2015-07-15 아도시아 치환된 음이온성 화합물을 포함하는 속효성 인슐린 제형
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9371264B2 (en) 2013-01-11 2016-06-21 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
ES2972423T3 (es) * 2015-07-28 2024-06-12 Lilly Co Eli Preparado farmacéutico para mejorar la absorción y la acción hipoglucemiante postprandial de la insulina
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
JP2019504684A (ja) * 2016-01-29 2019-02-21 マンカインド コーポレイション 乾燥粉末吸入器
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
EP3515430A1 (en) 2016-09-26 2019-07-31 United Therapeutics Corporation Treprostinil prodrugs
AU2017334290B2 (en) 2016-09-29 2023-04-20 Arecor Limited Novel formulations
MA49116A (fr) 2016-12-16 2020-03-25 Novo Nordisk As Compositions pharmaceutiques contenant de l'insuline
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
WO2018222787A1 (en) * 2017-06-01 2018-12-06 Eli Lilly And Company Rapid-acting insulin compositions
WO2019193349A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
IL277721B2 (en) 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump system for the delivery of an insulin compound
US20210113763A1 (en) 2018-04-04 2021-04-22 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
US12102610B2 (en) 2018-09-18 2024-10-01 Eli Lilly And Company Treprostinil salt
US10799564B1 (en) 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same
CN114096269B (zh) 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂
JP2022546314A (ja) 2019-08-23 2022-11-04 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグ
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations
US11826327B2 (en) 2020-04-17 2023-11-28 United Therapeutics Corporation Treatment for interstitial lung disease
KR20250057075A (ko) 2020-06-09 2025-04-28 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐의 푸마릴 디케토피페리딘 프로드러그
TW202214292A (zh) * 2020-06-30 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 速效胰島素組成物及其醫藥用途
JP7826317B2 (ja) 2020-12-14 2026-03-09 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグで疾患を治療する方法
EP4301372A1 (en) 2021-03-03 2024-01-10 United Therapeutics Corporation A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)
KR20250002687A (ko) * 2022-04-29 2025-01-07 자오커 파마슈티컬 (광저우) 컴퍼니., 리미티드 트레프로스티닐 소프트 미스트 흡입제

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2740953A1 (de) 1977-09-12 1979-03-22 Thera Ges Fuer Patente Verwendung von prostaglandinen zur senkung des blutzuckerspiegels
JPH10251146A (ja) * 1997-03-11 1998-09-22 Toray Ind Inc 糖尿病性神経障害の治療方法
WO2003020201A2 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
ATE496064T1 (de) * 2002-05-07 2011-02-15 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
CN101287457B (zh) * 2004-04-12 2011-11-16 联合治疗公司 Treprostinil用于治疗神经性糖尿病的足部溃疡的用途
EP2190433A2 (en) * 2007-08-22 2010-06-02 Gilead Colorado, Inc. Therapy for complications of diabetes
US9387033B2 (en) 2008-08-28 2016-07-12 Roche Diabetes Care, Inc. Device and method for enhanced subcutaneous insulin absorption
EP2330893A4 (en) * 2008-09-25 2013-01-09 Aradigm Corp DEEP PULMONARY ADMINISTRATION OF TREPROSTINIL
KR101775000B1 (ko) 2009-06-26 2017-09-04 노보 노르디스크 에이/에스 인슐린, 니코틴아미드 및 아미노산을 포함하는 제제
BR112012011237A2 (pt) * 2009-11-13 2019-09-24 Univ Tokyo agente terapêutico e profilático para diabetes
CN103328006A (zh) 2010-12-14 2013-09-25 诺沃—诺迪斯克有限公司 包含胰岛素、烟酰胺和氨基酸的制剂
JP6092867B2 (ja) * 2011-08-12 2017-03-08 アセンディス ファーマ エー／エス 担体連結しているトレプロスチニルプロドラッグ
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US20150065423A1 (en) 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
WO2015120457A1 (en) 2014-02-10 2015-08-13 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations

Also Published As

Publication number Publication date
PT3536380T (pt) 2021-09-02
EA031134B1 (ru) 2018-11-30
US9439952B2 (en) 2016-09-13
IL248350B (en) 2020-03-31
EA201691911A1 (ru) 2017-02-28
UA124919C2 (uk) 2021-12-15
AU2015256355B2 (en) 2017-09-14
DK3536380T3 (da) 2021-08-02
KR20160133567A (ko) 2016-11-22
PH12016502195A1 (en) 2017-02-06
CA2945188C (en) 2018-12-11
ME03384B (me) 2020-01-20
HUE055742T2 (hu) 2021-12-28
HRP20211415T1 (hr) 2021-12-10
TR201906843T4 (tr) 2019-05-21
PE20161408A1 (es) 2016-12-28
EP3536380B8 (en) 2021-09-22
PT3140008T (pt) 2019-06-25
TN2016000443A1 (en) 2018-04-04
CL2016002772A1 (es) 2017-06-09
JO3624B1 (ar) 2020-08-27
SI3536380T1 (sl) 2021-09-30
RS62291B1 (sr) 2021-09-30
PH12016502195B1 (en) 2017-02-06
MX2016014643A (es) 2017-03-06
EP3140008A1 (en) 2017-03-15
LT3536380T (lt) 2021-08-10
CY1121669T1 (el) 2020-07-31
BR112016024357A2 (pt) 2017-10-10
US10172922B2 (en) 2019-01-08
SG11201608424WA (en) 2016-11-29
EP3536380A1 (en) 2019-09-11
AU2015256355A1 (en) 2016-10-27
AP2016009525A0 (en) 2016-10-31
AR100155A1 (es) 2016-09-14
CA2945188A1 (en) 2015-11-12
JP6050902B2 (ja) 2016-12-21
EP3943155A1 (en) 2022-01-26
DK3140008T3 (da) 2019-06-24
MA39441A1 (fr) 2017-06-30
PL3140008T3 (pl) 2019-09-30
MX367521B (es) 2019-08-26
KR101858890B1 (ko) 2018-05-16
CN106456717B (zh) 2020-01-17
ES2891983T3 (es) 2022-02-01
HRP20190777T1 (hr) 2019-08-23
JP2016523807A (ja) 2016-08-12
HUE044370T2 (hu) 2019-10-28
SI3140008T1 (sl) 2019-06-28
ES2733639T3 (es) 2019-12-02
CN106456717A (zh) 2017-02-22
US20160367640A1 (en) 2016-12-22
EP3140008B1 (en) 2019-04-17
US20160129087A1 (en) 2016-05-12
EP3536380B1 (en) 2021-07-07
IL248350A0 (en) 2016-11-30
TWI685348B (zh) 2020-02-21
TW201625291A (zh) 2016-07-16
BR112016024357B1 (pt) 2022-08-23
WO2015171484A1 (en) 2015-11-12
NZ724919A (en) 2018-01-26
LT3140008T (lt) 2019-05-27
CY1124454T1 (el) 2022-07-22
RS58726B1 (sr) 2019-06-28

Similar Documents

Publication Publication Date Title
DK3140008T3 (da) Hurtigtvirkende insulinsammensætninger
DK3130649T3 (da) Haloolefin-baseret sammensætning
DK3233108T3 (da) Hurtigtvirkende insulinsammensætninger
BR112016030368A2 (pt) composição oftálmica
DK3215173T3 (da) Glycopeptidsammensætninger
MA41107A (fr) Compositions anti-cancéreuses
DK3198111T3 (da) Forbedret prop
FR3024363B1 (fr) Composition thermogelifiable
LT3226842T (lt) Priešvėžinės kompozicijos
LT3226843T (lt) Priešvėžinės kompozicijos
DK3171700T3 (da) Infusionsanlæg
DK3129007T3 (da) Vaccinesammensætninger
CL2017000639A1 (es) Composición
DK3331498T3 (da) Nasalsammensætning
EP3236746C0 (en) COMPOSITION
DK3200827T3 (da) Sammensætninger
DK3148513T3 (da) Ceritinib-formulering
DK3217964T3 (da) Sammensætning
DK3193856T3 (da) Formulering
DK3089740T3 (da) Farmaceutisk sammensætning
FR3019552B1 (fr) Composition filmogene
DK3001076T3 (da) Tilbageløbsforhindrer
DK3160441T3 (da) Flydende thioureylensammensætninger
DK3119380T3 (da) Sammensætning omfattende biprodukter
UA28872S (uk) Шприц